Acceleron Pharma (NASDAQ:XLRN) released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02), Bloomberg Earnings reports. Acceleron Pharma had a negative net margin of 804.49% and a negative return on equity of 38.71%. The business had revenue of $3.71 million during the quarter, compared to analyst estimates of $3.39 million.
Shares of Acceleron Pharma (NASDAQ XLRN) traded down $0.35 during trading on Wednesday, hitting $44.23. The stock had a trading volume of 140,981 shares, compared to its average volume of 315,722. The company has a market capitalization of $2,018.88, a price-to-earnings ratio of -16.53 and a beta of 1.39. Acceleron Pharma has a 12 month low of $24.37 and a 12 month high of $46.93.
In related news, SVP Christopher Rovaldi sold 2,266 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $42.42, for a total transaction of $96,123.72. Following the sale, the senior vice president now owns 52,977 shares in the company, valued at $2,247,284.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard F. Pops sold 37,500 shares of the company’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $41.42, for a total value of $1,553,250.00. Following the sale, the director now owns 68,750 shares in the company, valued at approximately $2,847,625. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 183,521 shares of company stock worth $7,082,848. Corporate insiders own 3.90% of the company’s stock.
XLRN has been the subject of several research analyst reports. Credit Suisse Group set a $51.00 price objective on Acceleron Pharma and gave the company a “buy” rating in a research report on Tuesday, November 14th. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, November 14th. HC Wainwright reissued a “buy” rating and issued a $62.00 target price on shares of Acceleron Pharma in a research note on Monday, December 11th. BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Finally, Cann reissued a “hold” rating on shares of Acceleron Pharma in a research note on Monday, January 8th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $47.06.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.